{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:43:34Z","timestamp":1785285814381,"version":"3.55.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":496,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023392","name":"NIHR Barts Biomedical Research Centre, Queen Mary University of London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023392","name":"NIHR Barts Biomedical Research Centre, Queen Mary University of London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Fluoropyrimidine chemotherapy is important for treatment of many solid tumours but is associated with cardiotoxicity. The relationship of fluoropyrimidine-associated cardiotoxicity (FAC) with conventional cardiovascular (CV) risk factors is poorly understood, and standard cardiovascular risk scores are not validated in this context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Single-centre retrospective study of patients treated with fluoropyrimidine chemotherapy using electronic health records for cardiovascular risk factors (and calculation of QRISK3 score), cancer treatment, and clinical outcomes. FAC was defined by cardiovascular events during or within 3 months of fluoropyrimidine treatment, and Cox regression was used to assess associations of CV risk and cancer treatment with FAC. One thousand eight hundred ninety-eight patients were included (45% male; median age 64 years), with median follow up 24.5 (11.5\u201348.3 months); 52.7% of patients were at moderate or high baseline CV risk (QRISK3 score &amp;gt;10%) Cardiovascular events occurred in 3.1% (59\/1898)\u2014most commonly angina (64.4%, 38\/59) and atrial fibrillation (13.6%, 8\/59), with 39% events during cycle one of treatment. In univariable analysis, QRISK3 score &amp;gt;20% was significantly associated with incident FAC (HR 2.25, 95% CI 1.11\u20134.93, P = 0.03). On multivariable analysis, beta-blocker use (HR 1.04, 95% CI 1.00\u20131.08, P = 0.04) and higher BMI (HR 2.33, 95% CI 1.04\u20135.19, P = 0.04) were independently associated with incident CV events. Thirty-two of the 59 patients with FAC were subsequently rechallenged with fluoropyrimidine chemotherapy, with repeat CV events in 6% (2\/32). Incident FAC did not affect overall survival (P = 0.50).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High BMI and use of beta-blockers are associated with risk of CV events during fluoropyrimidine chemotherapy. QRISK3 score may also play a role in identifying patients at high risk of CV events during fluoropyrimidine chemotherapy. Re-challenge with further fluoropyrimidine chemotherapy can be considered in patients following CV events during prior treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14879","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:59:39Z","timestamp":1717721979000},"page":"3041-3051","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predicting Cardiovascular Events with Fluoropyrimidine Chemotherapy Using a Standard Cardiovascular Risk Calculator"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-3551","authenticated-orcid":false,"given":"Aderonke","family":"Abiodun","sequence":"first","affiliation":[{"name":"Barts Heart Centre, Barts Health NHS Trust , London ,","place":["UK"]},{"name":"Institute of Cardiovascular Science, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Shawe-Taylor","sequence":"additional","affiliation":[{"name":"Barts Heart Centre, Barts Health NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Tyebally","sequence":"additional","affiliation":[{"name":"Barts Heart Centre, Barts Health NHS Trust , London ,","place":["UK"]},{"name":"Institute of Cardiovascular Science, University College London , London ,","place":["UK"]},{"name":"National University Health System , Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Bagkeris","sequence":"additional","affiliation":[{"name":"Great Ormond Street Institute of Child Health , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omotomilola","family":"Bajomo","sequence":"additional","affiliation":[{"name":"Barts Heart Centre, Barts Health NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Artico","sequence":"additional","affiliation":[{"name":"Barts Heart Centre, Barts Health NHS Trust , London ,","place":["UK"]},{"name":"Institute of Cardiovascular Science, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Slater","sequence":"additional","affiliation":[{"name":"Barts Cancer Centre, Barts Health NHS Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Raisi-Estabragh","sequence":"additional","affiliation":[{"name":"Barts Heart Centre, Barts Health NHS Trust , London ,","place":["UK"]},{"name":"William Harvey Research Institute, Queen Mary University London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Diamantis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Royal Free London NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-7090","authenticated-orcid":false,"given":"Charlotte","family":"Manisty","sequence":"additional","affiliation":[{"name":"Barts Heart Centre, Barts Health NHS Trust , London ,","place":["UK"]},{"name":"Institute of Cardiovascular Science, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"2026012113142168100_ehf214879-bib-0001","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2026012113142168100_ehf214879-bib-0002","doi-asserted-by":"publisher","first-page":"v184","DOI":"10.1093\/annonc\/mdq185","article-title":"Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Gr\u00e9goire","year":"2010","journal-title":"Ann Oncol"},{"key":"2026012113142168100_ehf214879-bib-0003","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"2026012113142168100_ehf214879-bib-0004","doi-asserted-by":"publisher","volume-title":"NICE National Institute for Health Care and Excellence. Colorectal cancer: diagnosis and management|Guidance and guidelines|NICE. Clinical Guideline (CG131)","year":"2014","DOI":"10.3768\/rtipress.2024.rb.0035.2402"},{"key":"2026012113142168100_ehf214879-bib-0005","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clcc.2012.09.003","article-title":"Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity","volume":"12","author":"Deboever","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"2026012113142168100_ehf214879-bib-0006","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012113142168100_ehf214879-bib-0007","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1517\/14740330902733961","article-title":"Fluoropyrimidine-associated cardiotoxicity: revisited","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"2026012113142168100_ehf214879-bib-0008","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.ejca.2005.03.027","article-title":"The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)","volume":"41","author":"Ng","year":"2005","journal-title":"Eur J Cancer"},{"key":"2026012113142168100_ehf214879-bib-0009","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.002","article-title":"Fluoropyrimidine-induced cardiotoxicity","volume":"124","author":"Depetris","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026012113142168100_ehf214879-bib-0010","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"2026012113142168100_ehf214879-bib-0011","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","article-title":"Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine","volume":"58","author":"Jensen","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026012113142168100_ehf214879-bib-0012","first-page":"660","article-title":"A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in pakistani adult cancer patients at shaukat khanum memorial cancer hospital & research center","volume":"62","author":"Khan","year":"2012","journal-title":"J Pak Med Assoc"},{"key":"2026012113142168100_ehf214879-bib-0013","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026012113142168100_ehf214879-bib-0014","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the cardio-oncology study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the international cardio-oncology society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012113142168100_ehf214879-bib-0015","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"key":"2026012113142168100_ehf214879-bib-0016","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/0284186X.2019.1711164","article-title":"Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer","volume":"59","author":"Dyhl-Polk","year":"2020","journal-title":"Acta Oncol (Madr)"},{"key":"2026012113142168100_ehf214879-bib-0017","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaccao.2020.12.005","article-title":"The incidence, risk factors, and outcomes with 5-fluorouracil\u2013associated coronary vasospasm","volume":"3","author":"Zafar","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026012113142168100_ehf214879-bib-0018","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/jjco\/hyi071","article-title":"Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up","volume":"35","author":"Meydan","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"2026012113142168100_ehf214879-bib-0019","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","article-title":"5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity","volume":"69","author":"Jensen","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026012113142168100_ehf214879-bib-0020","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1159\/000331645","article-title":"Clinical and electrocardiography changes in patients treated with capecitabine","volume":"57","author":"Koca","year":"2012","journal-title":"Chemotherapy"},{"key":"2026012113142168100_ehf214879-bib-0021","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.critrevonc.2021.103346","article-title":"Risk factors of fluoropyrimidine induced cardiotoxicity among cancer patients: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026012113142168100_ehf214879-bib-0022","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1017237","article-title":"Risk factors for fluoropyrimidine-induced cardiotoxicity in colorectal cancer: a retrospective cohort study and establishment of a prediction nomogram for 5-FU induced cardiotoxicity","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"2026012113142168100_ehf214879-bib-0023","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.clcc.2018.10.006","article-title":"5-fluorouracil-related cardiotoxicity; findings from five randomized studies of 5-fluorouracil-based regimens in metastatic colorectal cancer","volume":"18","author":"Abdel-Rahman","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"2026012113142168100_ehf214879-bib-0024","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1002\/cphy.c210014","article-title":"Obesity, body composition, and sex hormones: implications for cardiovascular risk","volume":"12","author":"Singh","year":"2021","journal-title":"Compr Physiol"},{"key":"2026012113142168100_ehf214879-bib-0025","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41366-023-01339-9","article-title":"Body composition and risk factors for cardiovascular disease in global multi-ethnic populations","volume":"47","author":"Carter","year":"2023","journal-title":"Int J Obes (Lond)"},{"key":"2026012113142168100_ehf214879-bib-0026","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.3390\/jcm10194426","article-title":"Cardiotoxicity of fluoropyrimidines: epidemiology, mechanisms, diagnosis, and management","volume":"10","author":"Jurczyk","year":"2021","journal-title":"J Clin Med"},{"key":"2026012113142168100_ehf214879-bib-0027","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2459\/JCM.0b013e32832e934b","article-title":"5-fluorouracil-induced coronary vasospasm","volume":"11","author":"Bathina","year":"2010","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026012113142168100_ehf214879-bib-0028","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/1078155211399164","article-title":"Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm","volume":"18","author":"Shah","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"2026012113142168100_ehf214879-bib-0029","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265767","article-title":"The efficacy and safety of cardio-protective therapy in patients with 5-FU (fluorouracil)-associated coronary vasospasm","volume":"17","author":"Zafar","year":"2022","journal-title":"PLoS ONE"},{"key":"2026012113142168100_ehf214879-bib-0030","doi-asserted-by":"publisher","first-page":"970","DOI":"10.21037\/jgo.2017.09.07","article-title":"Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm","volume":"8","author":"Clasen","year":"2017","journal-title":"J Gastrointest Oncol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/3041\/64514868\/eschf_11_5_3041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/3041\/64514868\/eschf_11_5_3041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:16:09Z","timestamp":1769019369000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/5\/3041\/8271212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,6,6]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14879","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,6,6]]},"assertion":[{"value":"2023-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}